CA3073142A1 - Morpholinylpyridone compounds - Google Patents

Morpholinylpyridone compounds Download PDF

Info

Publication number
CA3073142A1
CA3073142A1 CA3073142A CA3073142A CA3073142A1 CA 3073142 A1 CA3073142 A1 CA 3073142A1 CA 3073142 A CA3073142 A CA 3073142A CA 3073142 A CA3073142 A CA 3073142A CA 3073142 A1 CA3073142 A1 CA 3073142A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
trifluoromethyl
acceptable salt
compound according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3073142A
Other languages
English (en)
French (fr)
Other versions
CA3073142C (en
Inventor
Johan Lindstrom
Rickard Forsblom
Jenny Viklund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sprint Bioscience AB
Original Assignee
Sprint Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience AB filed Critical Sprint Bioscience AB
Publication of CA3073142A1 publication Critical patent/CA3073142A1/en
Application granted granted Critical
Publication of CA3073142C publication Critical patent/CA3073142C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3073142A 2017-08-23 2018-08-23 Morpholinylpyridone compounds Active CA3073142C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23
EP17187567.7 2017-08-23
PCT/EP2018/072791 WO2019038390A1 (en) 2017-08-23 2018-08-23 MORPHOLINYLPYRIDONE COMPOUNDS

Publications (2)

Publication Number Publication Date
CA3073142A1 true CA3073142A1 (en) 2019-02-28
CA3073142C CA3073142C (en) 2025-09-16

Family

ID=

Also Published As

Publication number Publication date
SI3672962T1 (sl) 2022-06-30
RU2020110506A3 (enExample) 2022-02-22
CY1125117T1 (el) 2024-12-13
PL3672962T3 (pl) 2022-05-02
SMT202200169T1 (it) 2022-05-12
WO2019038390A1 (en) 2019-02-28
AU2023285995A1 (en) 2024-01-25
IL272815B (en) 2022-06-01
ES2910157T3 (es) 2022-05-11
IL292489A (en) 2022-06-01
RU2020110506A (ru) 2021-09-23
CN111108102A (zh) 2020-05-05
HRP20220497T1 (hr) 2022-05-27
KR102732013B1 (ko) 2024-11-18
AU2018320419A1 (en) 2020-04-09
TWI803511B (zh) 2023-06-01
JP7199736B2 (ja) 2023-01-06
RS63109B1 (sr) 2022-04-29
JP2020531485A (ja) 2020-11-05
US20200361922A1 (en) 2020-11-19
KR20200044025A (ko) 2020-04-28
LT3672962T (lt) 2022-05-10
EP4056569A1 (en) 2022-09-14
US11560374B2 (en) 2023-01-24
CN116444510A (zh) 2023-07-18
HUE058661T2 (hu) 2022-09-28
PT3672962T (pt) 2022-04-12
TW202348601A (zh) 2023-12-16
CN116462674A (zh) 2023-07-21
IL292489B1 (en) 2023-05-01
EP3672962B1 (en) 2022-01-26
IL292489B2 (en) 2023-09-01
TW201912161A (zh) 2019-04-01
JP2023021268A (ja) 2023-02-10
US20230234949A1 (en) 2023-07-27
EP3672962A1 (en) 2020-07-01
AU2018320419B2 (en) 2023-09-28
DK3672962T3 (da) 2022-05-02
IL302077A (en) 2023-06-01
IL272815A (en) 2020-04-30
CN111108102B (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
US11963963B2 (en) 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
AU2021215234B2 (en) 6-Aryl-4-Morpholin-1-Ylpyridone Compounds Useful For The Treatment Of Cancer And Diabetes
AU2023285995A1 (en) Morpholinylpyridone Compounds
AU2023258375A1 (en) Pyridylpyridone Compounds
CA3073142C (en) Morpholinylpyridone compounds
HK40079060A (en) Morpholinylpyridone compounds
RU2803158C2 (ru) Морфолинилпиридоны
HK40030345B (en) Morpholinylpyridone compounds
CA3015005C (en) 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
CA3073129A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923